Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed competition impacts on the company's primary product [3][5]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical and its executives made false or misleading statements regarding the demand for their primary product, the Lapiplasty 3D Bunion Correction System, and failed to disclose competitive pressures affecting revenue [5]. - Following a press release on May 7, 2024, the company lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million, indicating significant revenue decline [6]. - The stock price of Treace Medical fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, following the announcement of the lowered revenue guidance [7]. Group 2: Legal Proceedings - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, are encouraged to discuss their legal rights and options, with a deadline of June 10, 2025, to seek the role of lead plaintiff in the federal securities class action [2][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Treace's conduct [9].

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Treace Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the ...

Group 1 - The Rosen Law Firm is reminding purchasers of Treace Medical Concepts, Inc. securities of the June 10, 2025 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Treace Medical securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the Class Period, Treace Medical made false or misleading statements regarding competition affecting the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5] - It is claimed that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [5] - The lawsuit asserts that the positive statements made by Treace Medical about its business and prospects were materially misleading [5] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms in securities class action settlements [4]

NEW YORK, May 30, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2025 lead plaintiff deadline.So what: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.W ...

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=150492&from=4CLASS PE ...

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [2][3]. Group 1: Allegations and Impact - The complaint alleges that Treace Medical failed to disclose competition's impact on the demand and utilization of its primary product [2] - As a result of these undisclosed factors, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Following the revelation of these issues, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action and must file their papers by June 10, 2025, to serve as lead plaintiff [3] - The lead plaintiff represents other class members in directing the litigation, but participation is not required to be eligible for recovery [3] Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=149528&from=4CLASS PE ...

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competitive pressure, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [3]. - The defendants' positive statements about the company's business and prospects were allegedly misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline set for June 10, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Treace Medical Concepts, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit claims that Treace Medical made false or misleading statements regarding its business operations and the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [4].